Your Messages Inbox
Your Article Summary
See Latest ArticlesSepracor Announces New Drug Submission to Health Canada for STEDESA as Adjunctive Treatment for Epilepsy
Sepracor, 08/11/09
Sepracor Inc. announced that its Canadian subsidiary, Sepracor Pharmaceuticals, Inc. , has submitted an application to the Therapeutic Products Directorate of Health Canada for eslicarbazepine acetate as adjunctive therapy in the treatment of partial–onset seizures in adults with epilepsy. The proposed trade name for eslicarbazepine acetate in both the U.S. and Canada is STEDESA.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Novartis receives approval in the European Union for Onbrez Breezhaler, a new once-daily bronchodilator for patients with COPD
Novartis, 12/04/09
Safety concerns slow new drug review and approval processes
Formulary , 12/02/09
Teva Announces The Submission Of A Biologics License Application (BLA) For XM02 For The Treatment Of Chemotherapy-Induced Neutropenia
Teva Pharmaceutical Industries, 12/02/09
Article Search
Sponsor